Signal Rx Pharmaceuticals, Crystec and ADYA are working on a dry powder drug formulation for potentially treating COVID-19-related illness.
The three companies’ collaboration for the dry powder formulation of SF2523 covers the treatment of pulmonary fibrosis, lung cancer and illnesses related to SARS-CoV-2, the virus causing COVID-19.
Get the full story at our sister site, Drug Discovery & Development.
Filed Under: Drug Delivery, Drug Discovery, Drug Discovery and Development, Infectious Disease
Tell Us What You Think!
You must be logged in to post a comment.